title: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
abstract: BACKGROUND
  Although the risk of human papillomavirus (HPV) infection is greatest in young women, women older than 25 years remain at risk. We present data from the VIVIANE study of the HPV 16/18 AS04-adjuvanted vaccine in adult women after 7 years of follow-up.
  
  
  METHODS
  In this phase 3, double-blind, randomised controlled trial, healthy women older than 25 years were enrolled (age stratified: 26-35 years, 36-45 years, and ≥46 years). Up to 15% in each age stratum had a history of HPV infection or disease. Women were randomly assigned (1:1) to receive HPV 16/18 vaccine or aluminium hydroxide control, with an internet-based system. The primary endpoint was vaccine efficacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (CIN1+) associated with HPV 16/18. We did analyses in the according-to-protocol cohort for efficacy and total vaccinated cohort. Data for the combined primary endpoint in the according-to-protocol cohort for efficacy were considered significant when the lower limit of the 96·2% CI around the point estimate was greater than 30%. For all other endpoints and cohorts, data were considered significant when the lower limit of the 96·2% CI was greater than 0%. This study is registered with ClinicalTrials.gov, number NCT00294047.
  
  
  RESULTS
  The first participant was enrolled on Feb 16, 2006, and the last study visit took place on Jan 29, 2014. 4407 women were in the according-to-protocol cohort for efficacy (n=2209 vaccine, n=2198 control) and 5747 women in the total vaccinated cohort (n=2877 vaccine, n=2870 control). At month 84, in women seronegative for the corresponding HPV type in the according-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or CIN1+ associated with HPV 16/18 was significant in all age groups combined (90·5%, 96·2% CI 78·6-96·5). Vaccine efficacy against HPV 16/18-related cytological abnormalities (atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion) and CIN1+ was also significant. We also noted significant cross-protective efficacy against 6-month persistent infection with HPV 31 (65·8%, 96·2% CI 24·9-85·8) and HPV 45 (70·7%, 96·2% CI 34·2-88·4). In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was significant (22·9%, 96·2% CI 4·8-37·7). Serious adverse events related to vaccination occurred in five (0·2%) of 2877 women in the vaccine group and eight (0·3%) of 2870 women in the control group.
  
  
  CONCLUSIONS
  In women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18 and CIN1+ irrespective of HPV type, and infection with non-vaccine types HPV 31 and HPV 45 over 7 years of follow-up.
  
  
  BACKGROUND
  GlaxoSmithKline Biologicals SA.
authors.affiliation: Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Electronic address: Cwheeler@salud.unm.edu.
authors.forename: Cosette M
authors.initials: CM
authors.lastname: Wheeler
authors.affiliation: Vaccines Trials Group, Telethon Kids Institute, Perth, WA, Australia; Sydney University Discipline of Child and Adolescent Health, Children's Hospital Westmead, Sydney, NSW, Australia.
authors.forename: S Rachel
authors.initials: SR
authors.lastname: Skinner
authors.affiliation: Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Laguna, Philippines.
authors.forename: M Rowena
authors.initials: MR
authors.lastname: Del Rosario-Raymundo
authors.affiliation: Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, VIC, Australia; Department of Microbiology, The Royal Children's Hospital, Parkville, VIC, Australia; Murdoch Childrens Research Institute, Parkville, VIC, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia.
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Garland
authors.affiliation: Department of Pediatrics, University of South Dakota, Sanford School of Medicine, Sanford Children's Specialty Clinic, Sioux Falls, SD, USA.
authors.forename: Archana
authors.initials: A
authors.lastname: Chatterjee
authors.affiliation: Research Centre on Public Health, National Institute of Public Health, Cuernavaca, Mexico.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lazcano-Ponce
authors.affiliation: Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, Mexico.
authors.forename: Jorge
authors.initials: J
authors.lastname: Salmerón
authors.affiliation: Canadian Center for Vaccinology, IWK Health Center and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada.
authors.forename: Shelly
authors.initials: S
authors.lastname: McNeil
authors.affiliation: Departments of Internal Medicine and Infectious Diseases, University of Iowa, Iowa City, IA, USA.
authors.forename: Jack T
authors.initials: JT
authors.lastname: Stapleton
authors.affiliation: Department of Obstetrics and Gynaecology, Université Laval and Clinique RSF, Québec, QC, Canada.
authors.forename: Céline
authors.initials: C
authors.lastname: Bouchard
authors.affiliation: Department of Obstetrics and Gynaecology, Jersey Shore University Medical Center, Neptune, NJ, USA.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Martens
authors.affiliation: Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Money
authors.affiliation: Parkway Gynaecology Screening and Treatment Centre, Gleneagles Hospital, Singapore, Singapore.
authors.forename: Swee Chong
authors.initials: SC
authors.lastname: Quek
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
authors.forename: Barbara
authors.initials: B
authors.lastname: Romanowski
authors.affiliation: Division de Investigacion, Oncosalud-AUNA, Lima, Peru.
authors.forename: Carlos S
authors.initials: CS
authors.lastname: Vallejos
authors.affiliation: Roosevelt Kliniek, Leiden, Netherlands.
authors.forename: Bram
authors.initials: B
authors.lastname: Ter Harmsel
authors.affiliation: Outpatient Department, Scientific Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation, Moscow, Russian.
authors.forename: Vera
authors.initials: V
authors.lastname: Prilepskaya
authors.affiliation: Singapore General Hospital, Singapore, Singapore.
authors.forename: Kah Leng
authors.initials: KL
authors.lastname: Fong
authors.affiliation: Department of Gynaecological Oncology, Women's Cancer Centre, University of Manchester, St Mary's Hospital, Manchester, UK.
authors.forename: Henry
authors.initials: H
authors.lastname: Kitchener
authors.affiliation: City Clinical Hospital, Moscow, Russian.
authors.forename: Galina
authors.initials: G
authors.lastname: Minkina
authors.affiliation: Department of Gynaecologic Oncology, KK Women's and Children's Hospital, Singapore, Singapore.
authors.forename: Yong Kuei Timothy
authors.initials: YKT
authors.lastname: Lim
authors.affiliation: Vaccines Trials Group, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
authors.forename: Tanya
authors.initials: T
authors.lastname: Stoney
authors.affiliation: Department of Obstetrics and Gynecology, Miler School of Medicine, University of Miami, Miami, FL, USA.
authors.forename: Nahida
authors.initials: N
authors.lastname: Chakhtoura
authors.affiliation: Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, Aberdeen, UK.
authors.forename: Margaret E
authors.initials: ME
authors.lastname: Cruickshank
authors.affiliation: Laboratory of Microbiology, DO Ott Research Institute of Obstetrics and Gynecology, St Petersburg, Russia.
authors.forename: Alevtina
authors.initials: A
authors.lastname: Savicheva
authors.affiliation: Departmento de Ginecologia, Instituto Português de Oncologia de Coimbra, Coimbra, Portugal.
authors.forename: Daniel Pereira
authors.initials: DP
authors.lastname: da Silva
authors.affiliation: Department of Family Medicine and Emergency Medicine, Colchester Research Group, Colchester Regional Hospital, Dalhousie University, Truro, NS, Canada.
authors.forename: Murdo
authors.initials: M
authors.lastname: Ferguson
authors.affiliation: DDL Diagnostic Laboratory, Rijswijk, Netherlands.
authors.forename: Anco C
authors.initials: AC
authors.lastname: Molijn
authors.affiliation: DDL Diagnostic Laboratory, Rijswijk, Netherlands.
authors.forename: Wim G V
authors.initials: WGV
authors.lastname: Quint
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Karin
authors.initials: K
authors.lastname: Hardt
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Dominique
authors.initials: D
authors.lastname: Descamps
authors.affiliation: GSK Pharmaceuticals India Ltd, Bangalore, India.
authors.forename: Pemmaraju V
authors.initials: PV
authors.lastname: Suryakiran
authors.affiliation: GSK Pharmaceuticals India Ltd, Bangalore, India.
authors.forename: Naveen
authors.initials: N
authors.lastname: Karkada
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Brecht
authors.initials: B
authors.lastname: Geeraerts
authors.affiliation: GSK Vaccines, King of Prussia, PA, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Dubin
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Frank
authors.initials: F
authors.lastname: Struyf
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D004279:DNA, Viral; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000276:immunology / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology
chemical_list: D000276:Adjuvants, Immunologic; D004279:DNA, Viral; D053918:Papillomavirus Vaccines